Skip to main content

According to an article recently published in the journal Cancer, certain patients diagnosed with Stage I non–small cell lung cancer (NSCLC) have a worse prognosis than their counterparts with this stage of disease.

Non–small cell lung cancer accounts for approximately 75–80% of all lung cancers in the United States. Lung cancer remains the leading cause of cancer-related deaths worldwide.

Stage I NSCLC refers to the earliest stage of lung cancer, prior to spread. Cure rate for patients with stage I NSCLC are good following standard therapies; however, a significant portion of patients will experience a cancer recurrence and ultimately succumb to their disease.

Researchers from California recently conducted a clinical study to evaluate potential variables that may be related to the risk of a cancer recurrence among patients with Stage I NSCLC. This study included over 19,700 patients identified in the California Cancer Registry between 1989 and 2003.

  • Advanced age at diagnosis, male sex, low socioeconomic status, treatment that did not include surgery, and poor histologic grade (microscopic structure indicating aggressive nature) were associated with increased mortality.
  • Cancer that was not located in an upper lobe of the lungs and a cancer larger than 4 centimeters also increased the risk of mortality.
  • Bronchioloalveolar carcinoma (type of NSCLC) and Asian ethnicity were associated with a decreased risk of mortality.

The researchers concluded: “Stage I NSCLC with poorly differentiated histology and stage IB NSCLC with nonupper lobar tumor location or tumor size [greater than] 4 cm carried an increased mortality risk.” Understanding a patient’s risk of a recurrence can help guide treatment decisions.

Scroll to Continue

Recommended Articles


Skin Care During Radiation Therapy

Learn how to prevent and manage skin related side effects from radiation therapy.

Image placeholder title

Tecentriq® Improves Survival in Early and Advanced Stage NSCLC

2022 World Lung Congress update for early stage disease -Tecentriq® Checkpoint Inhibitor immunotherapy improves survival in early and advanced stage non-small cell lung cancers.

Patients diagnosed with Stage I NSCLC may wish to discuss their individual risks and benefits of all treatment options with their physician.

Reference: Ou S-H, Zell J, Ziogas A, Anton-Culver H. Prognostic factors for survival of Stage I non–small cell lung cancer patients. Cancer. 2007;110:1532 – 1541.

Related News:

Gene Expression Linked with Prognosis in Early-stage Non–Small Cell Lung Cancer (09/17/2007)

Smokers Have Worse Lung Cancer Outcomes than Nonsmokers (07/19/2007)

Copyright Lung Cancer Information Center on

Copyright © 2018 CancerConnect. All Rights Reserved.